Blog

Tanja Obradovic

Jun 24, 2025, 05:53

Tanja Obradovic: Teva Pharmaceuticals and Fosun Pharma Partnership on Anti-PD1-IL2 Immunotherapy

Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:

“Getting new promising immunooncology drug to the clinic is a complex task that involves navigation across well planned strategy beyond clinical development to include generation of clinical and market access value evidence before and post-launch. Multiple companies joining hands to tackle from the points of their strengths is one of the recent trends.

With announcement from few days ago Teva Pharmaceuticals, known for excellency in biosimilar arena including late stage development and post launch evidence generation, is opening new direction into novel oncology products in partnership with innovative China-based Fosun Pharma whose expertise is rapid entering and managing early clinical space oncology development across different drug modalities.

Teva’s TEV-56278 is an anti-PD-1 antibody-cytokine fusion protein (anti-PD1-IL2 ATTENUKINE) designed to selectively deliver interleukin-2 to PD-1-expressing T cells within the tumor microenvironment, with the goal of amplifying anti-tumor T-cell activity while minimizing systemic toxicities. TEV-5678 is being evaluated as both a monotherapy and in combination with Merck’s Keytruda (pembrolizumab) in ongoing Phase I trial.

Relapsed/refractory patients with various advanced solid tumors are eligible and 240 patients are to be enrolled at 10 sites (ongoing at 9 US and 1 Canada site). Trial started mid-last year so first clinical data showing safety and initial magnitude of the efficacy signal may be coming soon.

Interesting to point is that in terms of geographical coverage partners seemed to focus on deep-rooted presence where Fosun Pharma will be granted an exclusive licence to develop, manufacture and commercialise TEV-56278 in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR and Taiwan region and select Southeast Asian countries, with Teva Pharmaceuticals retaining all rights in the rest of the world.”

Read Further.

More posts featuring Tanja Obradovic.